Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Pacific Biosciences of California Plunged 23% Today

By Travis Hoium - Feb 4, 2016 at 12:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Disappointing revenue and a new share offering plan had investors selling Pacific Biosciences of California today.

What: Shares of gene sequencing company Pacific Biosciences of California (PACB -4.54%) plunged 23% in midday trading on Thursday after the company reported earnings that underwhelmed investors.

So what: Fourth-quarter revenue surged 115% to $36.3 million on the back of a $20 million contractual milestone payment from Roche. But that still fell short of the $38.4 million in revenue that analysts expected. On the bottom line, net loss improved from $19.0 million a year ago to a $1.4 million loss, or $0.02 per share, which met expectations.  

The bigger news may be that Pacific Biosciences announced it will sell as much as $30 million in shares on the open market, causing further dilution to shareholders.  

Now what: Pacific Biosciences is in the midst of transitioning to a new product called the Sequel System that was launched in Q4 and that makes making or meeting estimates tough. Management said initial demand for Sequel has been strong, but it's going to ramp up slowly in 2016 so it has a smooth launch. That could be part of the disappointment today, with investors expecting a quicker ramp.

I don't think the fundamental story for Pacific Biosciences has changed, but there's uncertainty about when the company may see a lot of revenue growth and when that may lead to breakeven cash flow. And that's not uncertainty investors are willing to buy today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
$5.07 (-4.54%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.